1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Low-Risk Non-Muscle-Invasive Bladder Cancer Treatment
1.2.3 Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Treatment
1.2.4 High-Risk Non-Muscle-Invasive Bladder Cancer Treatment
1.3 Market by Application
1.3.1 Global Non-Muscle-Invasive Bladder Cancer Treatment Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Non-Muscle-Invasive Bladder Cancer Treatment Market Perspective (2017-2028)
2.2 Non-Muscle-Invasive Bladder Cancer Treatment Growth Trends by Region
2.2.1 Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Non-Muscle-Invasive Bladder Cancer Treatment Historic Market Size by Region (2017-2022)
2.2.3 Non-Muscle-Invasive Bladder Cancer Treatment Forecasted Market Size by Region (2023-2028)
2.3 Non-Muscle-Invasive Bladder Cancer Treatment Market Dynamics
2.3.1 Non-Muscle-Invasive Bladder Cancer Treatment Industry Trends
2.3.2 Non-Muscle-Invasive Bladder Cancer Treatment Market Drivers
2.3.3 Non-Muscle-Invasive Bladder Cancer Treatment Market Challenges
2.3.4 Non-Muscle-Invasive Bladder Cancer Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-Muscle-Invasive Bladder Cancer Treatment Players by Revenue
3.1.1 Global Top Non-Muscle-Invasive Bladder Cancer Treatment Players by Revenue (2017-2022)
3.1.2 Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share by Players (2017-2022)
3.2 Global Non-Muscle-Invasive Bladder Cancer Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-Muscle-Invasive Bladder Cancer Treatment Revenue
3.4 Global Non-Muscle-Invasive Bladder Cancer Treatment Market Concentration Ratio
3.4.1 Global Non-Muscle-Invasive Bladder Cancer Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Muscle-Invasive Bladder Cancer Treatment Revenue in 2021
3.5 Non-Muscle-Invasive Bladder Cancer Treatment Key Players Head office and Area Served
3.6 Key Players Non-Muscle-Invasive Bladder Cancer Treatment Product Solution and Service
3.7 Date of Enter into Non-Muscle-Invasive Bladder Cancer Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Muscle-Invasive Bladder Cancer Treatment Breakdown Data by Type
4.1 Global Non-Muscle-Invasive Bladder Cancer Treatment Historic Market Size by Type (2017-2022)
4.2 Global Non-Muscle-Invasive Bladder Cancer Treatment Forecasted Market Size by Type (2023-2028)
5 Non-Muscle-Invasive Bladder Cancer Treatment Breakdown Data by Application
5.1 Global Non-Muscle-Invasive Bladder Cancer Treatment Historic Market Size by Application (2017-2022)
5.2 Global Non-Muscle-Invasive Bladder Cancer Treatment Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Non-Muscle-Invasive Bladder Cancer Treatment Market Size (2017-2028)
6.2 North America Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2017-2022)
6.3 North America Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Non-Muscle-Invasive Bladder Cancer Treatment Market Size (2017-2028)
7.2 Europe Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2017-2022)
7.3 Europe Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-Muscle-Invasive Bladder Cancer Treatment Market Size (2017-2028)
8.2 Asia-Pacific Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2017-2022)
8.3 Asia-Pacific Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Non-Muscle-Invasive Bladder Cancer Treatment Market Size (2017-2028)
9.2 Latin America Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2017-2022)
9.3 Latin America Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Market Size (2017-2028)
10.2 Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2017-2022)
10.3 Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Ferring Pharmaceuticals
11.1.1 Ferring Pharmaceuticals Company Detail
11.1.2 Ferring Pharmaceuticals Business Overview
11.1.3 Ferring Pharmaceuticals Non-Muscle-Invasive Bladder Cancer Treatment Introduction
11.1.4 Ferring Pharmaceuticals Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2017-2022)
11.1.5 Ferring Pharmaceuticals Recent Development
11.2 Merck
11.2.1 Merck Company Detail
11.2.2 Merck Business Overview
11.2.3 Merck Non-Muscle-Invasive Bladder Cancer Treatment Introduction
11.2.4 Merck Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2017-2022)
11.2.5 Merck Recent Development
11.3 Sesen Bio
11.3.1 Sesen Bio Company Detail
11.3.2 Sesen Bio Business Overview
11.3.3 Sesen Bio Non-Muscle-Invasive Bladder Cancer Treatment Introduction
11.3.4 Sesen Bio Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2017-2022)
11.3.5 Sesen Bio Recent Development
11.4 CG Oncology
11.4.1 CG Oncology Company Detail
11.4.2 CG Oncology Business Overview
11.4.3 CG Oncology Non-Muscle-Invasive Bladder Cancer Treatment Introduction
11.4.4 CG Oncology Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2017-2022)
11.4.5 CG Oncology Recent Development
11.5 ImmunityBio
11.5.1 ImmunityBio Company Detail
11.5.2 ImmunityBio Business Overview
11.5.3 ImmunityBio Non-Muscle-Invasive Bladder Cancer Treatment Introduction
11.5.4 ImmunityBio Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2017-2022)
11.5.5 ImmunityBio Recent Development
11.6 Theralase
11.6.1 Theralase Company Detail
11.6.2 Theralase Business Overview
11.6.3 Theralase Non-Muscle-Invasive Bladder Cancer Treatment Introduction
11.6.4 Theralase Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2017-2022)
11.6.5 Theralase Recent Development
11.7 Viventia Bio Inc.
11.7.1 Viventia Bio Inc. Company Detail
11.7.2 Viventia Bio Inc. Business Overview
11.7.3 Viventia Bio Inc. Non-Muscle-Invasive Bladder Cancer Treatment Introduction
11.7.4 Viventia Bio Inc. Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2017-2022)
11.7.5 Viventia Bio Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
